Sign In

Login

Password

Forgot Password ? Sign Up

Czerniak (nowotwór) (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Czerniak (nowotwór)" in Polish language version.

refsWebsite
Global rank Polish rank
209nih.gov
4th place
7th place
139doi.org
2nd place
6th place
6web.archive.org
1st place
1st place
4google.pl
low place
557th place
3archive.ph
756th place
32nd place
2wiley.com
222nd place
228th place
2nature.com
234th place
204th place
2nejm.org
2,374th place
2,071st place
2ascopubs.org
low place
8,458th place
1viamedica.pl
low place
585th place
1zalecenia.med.pl
low place
low place
1mayoclinic.org
1,610th place
4,301st place
1miroslawstraczynski.pl
low place
low place
1czytelniamedyczna.pl
low place
1,047th place
1who.int
195th place
256th place
1docplayer.pl
low place
446th place
1onkologia.org.pl
low place
8,813th place
1aafp.org
1,916th place
4,399th place
1phmd.pl
low place
2,720th place
1cancerresearchuk.org
8,489th place
low place
1mp.pl
8,738th place
165th place
1asco.org
low place
low place
1cancernetwork.com
low place
low place
1termedia.pl
low place
624th place
1globenewswire.com
2,614th place
8,128th place
1thecco.net
low place
low place
1sagepub.com
731st place
848th place

aafp.org

archive.ph

asco.org

meetinglibrary.asco.org

ascopubs.org

jco.ascopubs.org

cancernetwork.com

cancerresearchuk.org

czytelniamedyczna.pl

docplayer.pl

doi.org

doi.org

  • A.G. Goodson, D. Grossman. Strategies for early melanoma detection: Approaches to the patient with nevi. „Journal of the American Academy of Dermatology”. 60 (5), s. 719-735; quiz 736-8, May 2009. DOI: 10.1016/j.jaad.2008.10.065. PMID: 19389517. 
  • D.S. Rigel. Epidemiology of melanoma. „Semin Cutan Med Surg”. 29 (4), s. 204–209, Dec 2010. DOI: 10.1016/j.sder.2010.10.005. PMID: 21277533. 
  • M. Berwick, E. Erdei, J. Hay. Melanoma epidemiology and public health. „Dermatol Clin”. 27 (2), s. 205-214, viii, Apr 2009. DOI: 10.1016/j.det.2008.12.002. PMID: 19254665. 
  • R.M. MacKie, A. Hauschild, A.M. Eggermont. Epidemiology of invasive cutaneous melanoma. „Ann Oncol”. 20 Suppl 6, s. vi1-7, Aug 2009. DOI: 10.1093/annonc/mdp252. PMID: 19617292. 
  • J.M. Elwood, R.P. Gallagher. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. „International Journal of Cancer”. 78 (3), s. 276–280, Oct 1998. DOI: <276::AID-IJC2>3.0.CO;2-S 10.1002/(SICI)1097-0215(19981029)78:3<276::AID-IJC2>3.0.CO;2-S. PMID: 9766557. 
  • K.E. Johnson, B.C. Wulff, T.M. Oberyszyn, T.A. Wilgus. Ultraviolet light exposure stimulates HMGB1 release by keratinocytes. „Archives of Dermatological Research”. 305 (9), s. 805–815, Nov 2013. DOI: 10.1007/s00403-013-1401-2. PMID: 23942756. 
  • S. Gandini, F. Sera, M.S. Cattaruzza, P. Pasquini i inni. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. „European Journal of Cancer”. 41 (1), s. 45–60, Jan 2005. DOI: 10.1016/j.ejca.2004.10.016. PMID: 15617990. 
  • R.P. Gallagher, J.J. Spinelli, T.K. Lee. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. „Cancer Epidemiol Biomarkers Prev”. 14 (3), s. 562–566, Mar 2005. DOI: 10.1158/1055-9965.EPI-04-0564. PMID: 15767329. 
  • A.K. Rustgi. Familial pancreatic cancer: genetic advances. „Genes & Development”. 28 (1), s. 1–7, Jan 2014. DOI: 10.1101/gad.228452.113. PMID: 24395243. 
  • C.B. Begg, I. Orlow, A.J. Hummer, B.K. Armstrong i inni. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. „J Natl Cancer Inst”. 97 (20), s. 1507–1515, Oct 2005. DOI: 10.1093/jnci/dji312. PMID: 16234564. 
  • S. Raimondi, F. Sera, S. Gandini, S. Iodice i inni. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. „Int J Cancer”. 122 (12), s. 2753–2760, Jun 2008. DOI: 10.1002/ijc.23396. PMID: 18366057. 
  • D. Zhang, C. Chen, X. Fu, S. Gu i inni. A meta-analysis of DNA repair gene XPC polymorphisms and cancer risk. „J Hum Genet”. 53 (1), s. 18–33, 2008. DOI: 10.1007/s10038-007-0215-5. PMID: 18097734. 
  • S. Blankenburg, I.R. König, R. Moessner, P. Laspe i inni. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. „Carcinogenesis”. 26 (6), s. 1085–1090, Jun 2005. DOI: 10.1093/carcin/bgi055. PMID: 15731165. 
  • R.C. Millikan, A. Hummer, C. Begg, J. Player i inni. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. „Carcinogenesis”. 27 (3), s. 610–618, Mar 2006. DOI: 10.1093/carcin/bgi252. PMID: 16258177. 
  • J. Han, G.A. Colditz, J.S. Liu, D.J. Hunter. Genetic variation in XPD, sun exposure, and risk of skin cancer. „Cancer Epidemiol Biomarkers Prev”. 14 (6), s. 1539–1544, Jun 2005. DOI: 10.1158/1055-9965.EPI-04-0846. PMID: 15941969. 
  • T. Debniak, R.J. Scott, B. Górski, C. Cybulski i inni. Common variants of DNA repair genes and malignant melanoma. „Eur J Cancer”. 44 (1), s. 110–114, Jan 2008. DOI: 10.1016/j.ejca.2007.10.006. PMID: 18024013. 
  • C. Li, Z. Liu, L.E. Wang, J.E. Gershenwald i inni. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. „Int J Cancer”. 122 (9), s. 2077–2084, May 2008. DOI: 10.1002/ijc.23357. PMID: 18183598. 
  • F.J. Moloney, H. Comber, P. O’Lorcain, P. O’Kelly i inni. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. „Br J Dermatol”. 154 (3), s. 498–504, Mar 2006. DOI: 10.1111/j.1365-2133.2005.07021.x. PMID: 16445782. 
  • M.P. Purdue, L. From, B.K. Armstrong, A. Kricker i inni. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. „Cancer Epidemiol Biomarkers Prev”. 14 (8), s. 2015–2022, Aug 2005. DOI: 10.1158/1055-9965.EPI-05-0097. PMID: 16103454. 
  • B.L. Diffey. Sunscreens and melanoma: the future looks bright. „Br J Dermatol”. 153 (2), s. 378–381, Aug 2005. DOI: 10.1111/j.1365-2133.2005.06729.x. PMID: 16086753. 
  • J.F. Aitken, P.H. Youl, M. Janda, J.B. Lowe i inni. Increase in skin cancer screening during a community-based randomized intervention trial. „Int J Cancer”. 118 (4), s. 1010–1016, Feb 2006. DOI: 10.1002/ijc.21455. PMID: 16152577. 
  • A. Pfahlberg, K.F. Kölmel, J.M. Grange, G. Mastrangelo i inni. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. „J Invest Dermatol”. 119 (3), s. 570–575, Sep 2002. DOI: 10.1046/j.1523-1747.2002.00643.x. PMID: 12230497. 
  • K.F. Kölmel, J.M. Grange, B. Krone, G. Mastrangelo i inni. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. „Eur J Cancer”. 41 (1), s. 118–125, Jan 2005. DOI: 10.1016/j.ejca.2004.09.023. PMID: 15617996. 
  • B. Krone, K.F. Kölmel, B.M. Henz, J.M. Grange. Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. „Eur J Cancer”. 41 (1), s. 104–117, Jan 2005. DOI: 10.1016/j.ejca.2004.08.010. PMID: 15617995. 
  • E. Erdei, S.M. Torres. A new understanding in the epidemiology of melanoma. „Expert Rev Anticancer Ther”. 10 (11), s. 1811–1823, Nov 2010. DOI: 10.1586/era.10.170. PMID: 21080806. 
  • H.S. Greenwald, E.B. Friedman, I. Osman. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. „Melanoma Res”. 22 (1), s. 1–8, Feb 2012. DOI: 10.1097/CMR.0b013e32834e6aa0. PMID: 22108608. 
  • G. Palmieri, M. Capone, M.L. Ascierto, G. Gentilcore i inni. Main roads to melanoma. „Journal of Translational Medicine”. 7, s. 86, 2009. DOI: 10.1186/1479-5876-7-86. PMID: 19828018. 
  • C. Bertolotto. Melanoma: from melanocyte to genetic alterations and clinical options. „Scientifica (Cairo)”. 2013, s. 635203, 2013. DOI: 10.1155/2013/635203. PMID: 24416617. 
  • M. Takata, H. Murata, T. Saida. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. „Pigment Cell & Melanoma Research”. 23 (1), s. 64–71, Feb 2010. DOI: 10.1111/j.1755-148X.2009.00645.x. PMID: 19788535. 
  • H. Tsao, L. Chin, L.A. Garraway, D.E. Fisher. Melanoma: from mutations to medicine. „Genes & Development”. 26 (11), s. 1131–1155, Jun 2012. DOI: 10.1101/gad.191999.112. PMID: 22661227. 
  • J.M. Mehnert, H.M. Kluger. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. „Curr Oncol Rep”. 14 (5), s. 449–457, Oct 2012. DOI: 10.1007/s11912-012-0249-5. PMID: 22723080. 
  • L. Mervic. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. „PLoS One”. 7 (3), s. e32955, 2012. DOI: 10.1371/journal.pone.0032955. PMID: 22412958. 
  • F. Tas. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. „Journal of Oncology”. 2012, s. 647684, 2012. DOI: 10.1155/2012/647684. PMID: 22792102. 
  • A. Kardynal, M. Olszewska. Modern non-invasive diagnostic techniques in the detection of early cutaneous melanoma. „J Dermatol Case Rep”. 8 (1), s. 1–8, Mar 2014. DOI: 10.3315/jdcr.2014.1161. PMID: 24748903. 
  • A. Blum, R. Hofmann-Wellenhof, H. Luedtke, U. Ellwanger i inni. Value of the clinical history for different users of dermoscopy compared with results of digital image analysis. „Journal of the European Academy of Dermatology”. 18 (6), s. 665–669, Nov 2004. DOI: 10.1111/j.1468-3083.2004.01044.x. PMID: 15482291. 
  • I. Tromme, L. Sacré, F. Hammouch, C. Legrand i inni. Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: results from an observational study. „British Journal of Dermatology”. 167 (4), s. 778–786, Oct 2012. DOI: 10.1111/j.1365-2133.2012.11042.x. PMID: 22564185. 
  • C. Longo, F. Farnetani, S. Ciardo, A.M. Cesinaro i inni. Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study of 140 cases. „British Journal of Dermatology”. 169 (1), s. 58–67, Jul 2013. DOI: 10.1111/bjd.12259. PMID: 23374159. 
  • D. Jasaitiene, S. Valiukeviciene, G. Linkeviciute, R. Raisutis i inni. Principles of high-frequency ultrasonography for investigation of skin pathology. „Journal of European Academy of Dermatology and Venereology”. 25 (4), s. 375–382, Apr 2011. DOI: 10.1111/j.1468-3083.2010.03837.x. PMID: 20849441. 
  • P. Mohr, A.M. Eggermont, A. Hauschild, A. Buzaid. Staging of cutaneous melanoma. „Annals of Oncology”. 20 Suppl 6, s. vi14-21, Aug 2009. DOI: 10.1093/annonc/mdp256. PMID: 19617293. 
  • H.C. Steinert, R.A. Huch Böni, A. Buck, R. Böni i inni. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. „Radiology”. 195 (3), s. 705–709, Jun 1995. DOI: 10.1148/radiology.195.3.7753998. PMID: 7753998. 
  • H.E. Daldrup-Link, C. Franzius, T.M. Link, D. Laukamp i inni. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. „American Journal of Roentgenology”. 177 (1), s. 229–236, Jul 2001. DOI: 10.2214/ajr.177.1.1770229. PMID: 11418435. 
  • S.B. Kesmodel, G.C. Karakousis, J.D. Botbyl, R.J. Canter i inni. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. „Annals of Surgical Oncology”. 12 (6), s. 449–458, Jun 2005. DOI: 10.1245/ASO.2005.04.027. PMID: 15864482. 
  • S.C. Paek, K.A. Griffith, T.M. Johnson, V.K. Sondak i inni. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. „Cancer”. 109 (1), s. 100–108, Jan 2007. DOI: 10.1002/cncr.22382. PMID: 17146784. 
  • U. Veronesi, N. Cascinelli, J. Adamus, C. Balch i inni. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. „N Engl J Med”. 318 (18), s. 1159–1162, May 1988. DOI: 10.1056/NEJM198805053181804. PMID: 3079582. 
  • J.M. Thomas, J. Newton-Bishop, R. A’Hern, G. Coombes i inni. Excision margins in high-risk malignant melanoma. „N Engl J Med”. 350 (8), s. 757–766, Feb 2004. DOI: 10.1056/NEJMoa030681. PMID: 14973217. 
  • J.H. Kunishige, D.G. Brodland, J.A. Zitelli. Surgical margins for melanoma in situ. „J Am Acad Dermatol”. 66 (3), s. 438–444, Mar 2012. DOI: 10.1016/j.jaad.2011.06.019. PMID: 22196979. 
  • D.L. Morton, J.F. Thompson, A.J. Cochran, N. Mozzillo i inni. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. „N Engl J Med”. 370 (7), s. 599–609, Feb 2014. DOI: 10.1056/NEJMoa1310460. PMID: 24521106. 
  • C. Mitteldorf, H.P. Bertsch, K. Jung, K.M. Thoms i inni. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. „Ann Surg Oncol”. 21 (7), s. 2252–2258, Jul 2014. DOI: 10.1245/s10434-014-3641-6. PMID: 24652352. 
  • S.L. Wong, C.M. Balch, P. Hurley, S.S. Agarwala i inni. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. „J Clin Oncol”. 30 (23), s. 2912–2918, Aug 2012. DOI: 10.1200/JCO.2011.40.3519. PMID: 22778321. 
  • N. Cascinelli, E. Bombardieri, R. Bufalino, T. Camerini i inni. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. „J Clin Oncol”. 24 (27), s. 4464–4471, Sep 2006. DOI: 10.1200/JCO.2006.06.3198. PMID: 16983115. 
  • J.H. Lee, R. Essner, H. Torisu-Itakura, L. Wanek i inni. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. „J Clin Oncol”. 22 (18), s. 3677–3684, Sep 2004. DOI: 10.1200/JCO.2004.01.012. PMID: 15365064. 
  • D.G. Varma, W.R. Richli, C. Charnsangavej, B.I. Samuels i inni. MR appearance of the distended iliopsoas bursa. „AJR Am J Roentgenol”. 156 (5), s. 1025–1028, May 1991. DOI: 10.2214/ajr.156.5.2017926. PMID: 2017926. 
  • A.M. Eggermont, S. Suciu, M. Santinami, A. Testori i inni. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. „Lancet”. 372 (9633), s. 117–126, Jul 2008. DOI: 10.1016/S0140-6736(08)61033-8. PMID: 18620949. 
  • J.Y. Chen, G. Hruby, R.A. Scolyer, R. Murali i inni. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. „Cancer”. 113 (10), s. 2770–2778, Nov 2008. DOI: 10.1002/cncr.23895. PMID: 18823042. 
  • S. Agrawal, J.M. Kane, B.A. Guadagnolo, W.G. Kraybill i inni. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. „Cancer”. 115 (24), s. 5836–5844, Dec 2009. DOI: 10.1002/cncr.24627. PMID: 19701906. 
  • B. Zbytek, J.A. Carlson, J. Granese, J. Ross i inni. Current concepts of metastasis in melanoma. „Expert Rev Dermatol”. 3 (5), s. 569–585, Oct 2008. DOI: 10.1586/17469872.3.5.569. PMID: 19649148. 
  • J.F. Thompson, P.C. Kam. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. „J Surg Oncol”. 88 (1), s. 1–3, Oct 2004. DOI: 10.1002/jso.20112. PMID: 15384062. 
  • G.M. Beasley, A. Caudle, R.P. Petersen, N.S. McMahon i inni. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. „J Am Coll Surg”. 208 (5), s. 706-715; discussion 715-7, May 2009. DOI: 10.1016/j.jamcollsurg.2008.12.019. PMID: 19476821. 
  • C.E. Boesch, T. Meyer, L. Waschke, S. Merkel i inni. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. „Int J Hyperthermia”. 26 (1), s. 16–20, Feb 2010. DOI: 10.3109/02656730903236086. PMID: 20100048. 
  • F. Spagnolo, P. Ghiorzo, L. Orgiano, L. Pastorino i inni. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. „Onco Targets Ther”. 8, s. 157–168, 2015. DOI: 10.2147/OTT.S39096. PMID: 25653539. 
  • P.A. Ascierto, J.M. Kirkwood, J.J. Grob, E. Simeone i inni. The role of BRAF V600 mutation in melanoma. „J Transl Med”. 10, s. 85, 2012. DOI: 10.1186/1479-5876-10-85. PMID: 22554099. 
  • H.C. Tang, Y.C. Chen. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. „Int J Nanomedicine”. 10, s. 3131–3146, 2015. DOI: 10.2147/IJN.S80150. PMID: 25960652. 
  • J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel i inni. Distinct sets of genetic alterations in melanoma. „N Engl J Med”. 353 (20), s. 2135–2147, Nov 2005. DOI: 10.1056/NEJMoa050092. PMID: 16291983. 
  • K.M. Ilieva, I. Correa, D.H. Josephs, P. Karagiannis i inni. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. „Mol Cancer Ther”. 13 (12), s. 2769–2783, Dec 2014. DOI: 10.1158/1535-7163.MCT-14-0290. PMID: 25385327. 
  • A.M. Menzies, G.V. Long, R. Murali. Dabrafenib and its potential for the treatment of metastatic melanoma. „Drug Des Devel Ther”. 6, s. 391–405, 2012. DOI: 10.2147/DDDT.S38998. PMID: 23251089. 
  • J. Wheler, R. Yelensky, G. Falchook, K.B. Kim i inni. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. „BMC Cancer”. 15, s. 61, 2015. DOI: 10.1186/s12885-015-1029-z. PMID: 25886620. 
  • C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski i inni. Improved overall survival in melanoma with combined dabrafenib and trametinib. „N Engl J Med”. 372 (1), s. 30–39, Jan 2015. DOI: 10.1056/NEJMoa1412690. PMID: 25399551. 
  • G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko i inni. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. „N Engl J Med”. 371 (20), s. 1877–1888, Nov 2014. DOI: 10.1056/NEJMoa1406037. PMID: 25265492. 
  • M.M. Chan, L.E. Haydu, A.M. Menzies, M.W. Azer i inni. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. „Cancer”. 120 (20), s. 3142–3153, Oct 2014. DOI: 10.1002/cncr.28851. PMID: 24985732. 
  • M.S. Carlino, K. Gowrishankar, C.A. Saunders, G.M. Pupo i inni. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. „Mol Cancer Ther”. 12 (7), s. 1332–1342, Jul 2013. DOI: 10.1158/1535-7163.MCT-13-0011. PMID: 23645591. 
  • A. Niezgoda, P. Niezgoda, R. Czajkowski. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. „Biomed Res Int”. 2015, s. 851387, 2015. DOI: 10.1155/2015/851387. PMID: 26171394. 
  • J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez i inni. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. „N Engl J Med”. 366 (8), s. 707–714, Feb 2012. DOI: 10.1056/NEJMoa1112302. PMID: 22356324. 
  • A. Swaika, J.A. Crozier, R.W. Joseph. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. „Drug Des Devel Ther”. 8, s. 775–787, 2014. DOI: 10.2147/DDDT.S31143. PMID: 24966667. 
  • P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen i inni. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. „N Engl J Med”. 364 (26), s. 2507–2516, Jun 2011. DOI: 10.1056/NEJMoa1103782. PMID: 21639808. 
  • P.A. Ascierto, D. Minor, A. Ribas, C. Lebbe i inni. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. „J Clin Oncol”. 31 (26), s. 3205–3211, Sep 2013. DOI: 10.1200/JCO.2013.49.8691. PMID: 23918947. 
  • K.T. Flaherty, C. Robert, P. Hersey, P. Nathan i inni. Improved survival with MEK inhibition in BRAF-mutated melanoma. „N Engl J Med”. 367 (2), s. 107–114, Jul 2012. DOI: 10.1056/NEJMoa1203421. PMID: 22663011. 
  • C. Robert, R. Dummer, R. Gutzmer, P. Lorigan i inni. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. „Lancet Oncol”. 14 (8), s. 733–740, Jul 2013. DOI: 10.1016/S1470-2045(13)70237-7. PMID: 23735514. 
  • I.C. Glitza, M.A. Davies. Genotyping of cutaneous melanoma. „Chin Clin Oncol”. 3 (3), s. 27, Sep 2014. DOI: 10.3978/j.issn.2304-3865.2014.03.01. PMID: 25632386. 
  • J. Guo, L. Si, Y. Kong, K.T. Flaherty i inni. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. „J Clin Oncol”. 29 (21), s. 2904–2909, Jul 2011. DOI: 10.1200/JCO.2010.33.9275. PMID: 21690468. 
  • D.M. Pardoll. The blockade of immune checkpoints in cancer immunotherapy. „Nat Rev Cancer”. 12 (4), s. 252–264, Apr 2012. DOI: 10.1038/nrc3239. PMID: 22437870. 
  • M.A. Postow, M.K. Callahan, J.D. Wolchok. Immune Checkpoint Blockade in Cancer Therapy. „J Clin Oncol”. 33 (17), s. 1974–1982, Jun 2015. DOI: 10.1200/JCO.2014.59.4358. PMID: 25605845. 
  • M. Atefi, E. Avramis, A. Lassen, D.J. Wong i inni. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. „Clin Cancer Res”. 20 (13), s. 3446–3457, Jul 2014. DOI: 10.1158/1078-0432.CCR-13-2797. PMID: 24812408. 
  • B. Homet Moreno, A. Ribas. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. „Br J Cancer”. 112 (9), s. 1421–1427, Apr 2015. DOI: 10.1038/bjc.2015.124. PMID: 25856776. 
  • O. Hamid, C. Robert, A. Daud, F.S. Hodi i inni. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. „N Engl J Med”. 369 (2), s. 134–144, Jul 2013. DOI: 10.1056/NEJMoa1305133. PMID: 23724846. 
  • T.C. Gangadhar, A.K. Salama. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. „Onco Targets Ther”. 8, s. 929–937, 2015. DOI: 10.2147/OTT.S53164. PMID: 25960664. 
  • A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf i inni. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. „Lancet Oncol”, Jun 2015. DOI: 10.1016/S1470-2045(15)00083-2. PMID: 26115796. 
  • S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger i inni. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. „N Engl J Med”. 366 (26), s. 2443–2454, Jun 2012. DOI: 10.1056/NEJMoa1200690. PMID: 22658127. 
  • S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger i inni. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. „J Clin Oncol”. 32 (10), s. 1020–1030, Apr 2014. DOI: 10.1200/JCO.2013.53.0105. PMID: 24590637. 
  • C. Robert, G.V. Long, B. Brady, C. Dutriaux i inni. Nivolumab in previously untreated melanoma without BRAF mutation. „N Engl J Med”. 372 (4), s. 320–330, Jan 2015. DOI: 10.1056/NEJMoa1412082. PMID: 25399552. 
  • J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow i inni. Nivolumab plus ipilimumab in advanced melanoma. „N Engl J Med”. 369 (2), s. 122–133, Jul 2013. DOI: 10.1056/NEJMoa1302369. PMID: 23724867. 
  • R.J. Greenwald, M.A. Oosterwegel, D. van der Woude, A. Kubal i inni. CTLA-4 regulates cell cycle progression during a primary immune response. „Eur J Immunol”. 32 (2), s. 366–373, Feb 2002. DOI: 10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5. PMID: 11807776. 
  • L.H. Camacho. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. „Cancer Med”. 4 (5), s. 661–672, May 2015. DOI: 10.1002/cam4.371. PMID: 25619164. 
  • A. Ito, S. Kondo, K. Tada, S. Kitano. Clinical Development of Immune Checkpoint Inhibitors. „Biomed Res Int”. 2015, s. 605478, 2015. DOI: 10.1155/2015/605478. PMID: 26161407. 
  • F.S. Hodi, S.J. O’Day, D.F. McDermott, R.W. Weber i inni. Improved survival with ipilimumab in patients with metastatic melanoma. „N Engl J Med”. 363 (8), s. 711–723, Aug 2010. DOI: 10.1056/NEJMoa1003466. PMID: 20525992. 
  • C. Robert, L. Thomas, I. Bondarenko, S. O’Day i inni. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. „N Engl J Med”. 364 (26), s. 2517–2526, Jun 2011. DOI: 10.1056/NEJMoa1104621. PMID: 21639810. 
  • D. Schadendorf, F.S. Hodi, C. Robert, J.S. Weber i inni. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. „J Clin Oncol”. 33 (17), s. 1889–1894, Jun 2015. DOI: 10.1200/JCO.2014.56.2736. PMID: 25667295. 
  • A. Ribas, R. Kefford, M.A. Marshall, C.J. Punt i inni. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. „J Clin Oncol”. 31 (5), s. 616–622, Feb 2013. DOI: 10.1200/JCO.2012.44.6112. PMID: 23295794. 
  • Jacek Mackiewicz, Łukasz Krokowicz. Immunotherapy in advanced cutaneous melanoma patients. „Przegląd Menopauzalny”, 2013. DOI: 10.5114/pm.2013.38599. 
  • M.L. Ascierto, I. Melero, P.A. Ascierto. Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. „Front Oncol”. 5, s. 152, 2015. DOI: 10.3389/fonc.2015.00152. PMID: 26217587. 
  • P.A. Ascierto, F.M. Marincola, M.B. Atkins. What’s new in melanoma? Combination!. „J Transl Med”. 13, s. 213, 2015. DOI: 10.1186/s12967-015-0582-1. PMID: 26141621. 
  • J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob i inni. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. „N Engl J Med”. 373 (1), s. 23–34, Jul 2015. DOI: 10.1056/NEJMoa1504030. PMID: 26027431. 
  • A.Y. Bedikian, M. Millward, H. Pehamberger, R. Conry i inni. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. „J Clin Oncol”. 24 (29), s. 4738–4745, Oct 2006. DOI: 10.1200/JCO.2006.06.0483. PMID: 16966688. 
  • P. Lui, R. Cashin, M. Machado, M. Hemels i inni. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. „Cancer Treat Rev”. 33 (8), s. 665–680, Dec 2007. DOI: 10.1016/j.ctrv.2007.06.004. PMID: 17919823. 
  • P.M. Patel, S. Suciu, L. Mortier, W.H. Kruit i inni. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). „Eur J Cancer”. 47 (10), s. 1476–1483, Jul 2011. DOI: 10.1016/j.ejca.2011.04.030. PMID: 21600759. 
  • R.D. Rao, S.G. Holtan, J.N. Ingle, G.A. Croghan i inni. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. „Cancer”. 106 (2), s. 375–382, Jan 2006. DOI: 10.1002/cncr.21611. PMID: 16342250. 
  • A. Pflugfelder, T.K. Eigentler, U. Keim, B. Weide i inni. Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. „PLoS One”. 6 (2), s. e16882, 2011. DOI: 10.1371/journal.pone.0016882. PMID: 21359173. 
  • D. Khayat, B. Giroux, J. Berille, V. Cour i inni. Fotemustine in the treatment of brain primary tumors and metastases. „Cancer Invest”. 12 (4), s. 414–420, 1994. DOI: 10.3109/07357909409038234. PMID: 8032964. 
  • M.F. Avril, S. Aamdal, J.J. Grob, A. Hauschild i inni. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. „J Clin Oncol”. 22 (6), s. 1118–1125, Mar 2004. DOI: 10.1200/JCO.2004.04.165. PMID: 15020614. 
  • M.B. Atkins, J. Hsu, S. Lee, G.I. Cohen i inni. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. „J Clin Oncol”. 26 (35), s. 5748–5754, Dec 2008. DOI: 10.1200/JCO.2008.17.5448. PMID: 19001327. 
  • N.J. Ives, R.L. Stowe, P. Lorigan, K. Wheatley. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. „J Clin Oncol”. 25 (34), s. 5426–5434, Dec 2007. DOI: 10.1200/JCO.2007.12.0253. PMID: 18048825. 
  • E. Maverakis, L.A. Cornelius, G.M. Bowen, T. Phan i inni. Metastatic melanoma - a review of current and future treatment options. „Acta Dermato-Venereologica”. 95 (5), s. 516–524, May 2015. DOI: 10.2340/00015555-2035. PMID: 25520039. 
  • A.M. Leung, D.M. Hari, D.L. Morton. Surgery for distant melanoma metastasis. „The Cancer Journal”. 18 (2). s. 176–184. DOI: 10.1097/PPO.0b013e31824bc981. PMID: 22453019. 
  • P.V. Dickson, J.E. Gershenwald. Staging and prognosis of cutaneous melanoma. „Surgical Oncology Clinics of North America”. 20 (1), s. 1–17, Jan 2011. DOI: 10.1016/j.soc.2010.09.007. PMID: 21111956. 
  • C.C. McLaughlin, X.C. Wu, A. Jemal, H.J. Martin i inni. Incidence of noncutaneous melanomas in the U.S.. „Cancer”. 103 (5), s. 1000–1007, Mar 2005. DOI: 10.1002/cncr.20866. PMID: 15651058. 
  • N. Seetharamu, P.A. Ott, A.C. Pavlick. Mucosal melanomas: a case-based review of the literature. „Oncologist”. 15 (7), s. 772–781, 2010. DOI: 10.1634/theoncologist.2010-0067. PMID: 20571149. 
  • B.E. Damato, S.E. Coupland. Ocular melanoma. „Saudi Journal of Ophthalmology”. 26 (2), s. 137–144, Apr 2012. DOI: 10.1016/j.sjopt.2012.02.004. PMID: 23960984. 
  • J.R. Wong, A.A. Nanji, A. Galor, C.L. Karp. Management of conjunctival malignant melanoma: a review and update. „Expert Review of Ophthalmology”. 9 (3), s. 185–204, Jun 2014. DOI: 10.1586/17469899.2014.921119. PMID: 25580155. 
  • P.R. Pereira, A.N. Odashiro, L.A. Lim, C. Miyamoto i inni. Current and emerging treatment options for uveal melanoma. „Journal of Clinical Ophthalmology”. 7, s. 1669–1682, 2013. DOI: 10.2147/OPTH.S28863. PMID: 24003303. 
  • I. Puusaari, J. Heikkonen, P. Summanen, A. Tarkkanen i inni. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. „Ophthalmology”. 110 (11), s. 2223–2234, Nov 2003. DOI: 10.1016/S0161-6420(03)00661-4. PMID: 14597534. 
  • B. Damato, I. Patel, I.R. Campbell, H.M. Mayles i inni. Local tumor control after 106Ru brachytherapy of choroidal melanoma. „International Journal of Radiation Oncology”. 63 (2), s. 385–391, Oct 2005. DOI: 10.1016/j.ijrobp.2005.02.017. PMID: 15913907. 
  • T.M. Aaberg, C.S. Bergstrom, Z.J. Hickner, M.J. Lynn. Long-term results of primary transpupillary thermal therapy for the treatment of choroidal malignant melanoma. „British Journal of Ophthalmology”. 92 (6), s. 741–746, Jun 2008. DOI: 10.1136/bjo.2007.132951. PMID: 18296506. 
  • J.W. Harbour, T.A. Meredith, P.A. Thompson, M.E. Gordon. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. „Ophthalmology”. 110 (11), s. 2207-2214; discussion 2215, Nov 2003. DOI: 10.1016/S0161-6420(03)00858-3. PMID: 14597531. 
  • A.A. Yarovoy, D.A. Magaramov, E.S. Bulgakova. The comparison of ruthenium brachytherapy and simultaneous transpupillary thermotherapy of choroidal melanoma with brachytherapy alone. „Brachytherapy”. 11 (3). s. 224–229. DOI: 10.1016/j.brachy.2011.09.007. PMID: 22104351. 
  • U.B. Hofmann, C.S. Kauczok-Vetter, R. Houben, J.C. Becker. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. „Clinical Cancer Research”. 15 (1), s. 324–329, Jan 2009. DOI: 10.1158/1078-0432.CCR-08-2243. PMID: 19118061. 
  • A. Calipel, S. Landreville, A. De La Fouchardière, F. Mascarelli i inni. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. „Clinical and Experimental Metastasis”. 31 (5), s. 553–564, Jun 2014. DOI: 10.1007/s10585-014-9649-2. PMID: 24652072. 
  • G.S. Falchook, K.D. Lewis, J.R. Infante, M.S. Gordon i inni. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. „The Lancet Oncology”. 13 (8), s. 782–789, Aug 2012. DOI: 10.1016/S1470-2045(12)70269-3. PMID: 22805292. 
  • J.M. Kirkwood, L. Bastholt, C. Robert, J. Sosman i inni. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. „Clinical Cancer Research”. 18 (2), s. 555–567, Jan 2012. DOI: 10.1158/1078-0432.CCR-11-1491. PMID: 22048237. 
  • R. Danielli, R. Ridolfi, V. Chiarion-Sileni, P. Queirolo i inni. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. „Cancer Immunol Immunother”. 61 (1), s. 41–48, Jan 2012. DOI: 10.1007/s00262-011-1089-0. PMID: 21833591. 
  • M. Del Vecchio, L. Di Guardo, P.A. Ascierto, A.M. Grimaldi i inni. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. „European Journal of Cancer”. 50 (1), s. 121–127, Jan 2014. DOI: 10.1016/j.ejca.2013.09.007. PMID: 24100024. 
  • J.A. Curtin, K. Busam, D. Pinkel, B.C. Bastian. Somatic activation of KIT in distinct subtypes of melanoma. „Journal of Clinical Oncology”. 24 (26), s. 4340–4346, Sep 2006. DOI: 10.1200/JCO.2006.06.2984. PMID: 16908931. 
  • F.S. Hodi, P. Friedlander, C.L. Corless, M.C. Heinrich i inni. Major response to imatinib mesylate in KIT-mutated melanoma. „Journal of Clinical Oncology”. 26 (12), s. 2046–2051, Apr 2008. DOI: 10.1200/JCO.2007.14.0707. PMID: 18421059. 
  • J. Lutzky, J. Bauer, B.C. Bastian. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. „Pigment Cell Melanoma Res”. 21 (4), s. 492–493, Aug 2008. DOI: 10.1111/j.1755-148X.2008.00475.x. PMID: 18510589. 
  • X. Jiang, J. Zhou, N.K. Yuen, C.L. Corless i inni. Imatinib targeting of KIT-mutant oncoprotein in melanoma. „Clinical Cancer Research”. 14 (23), s. 7726–7732, Dec 2008. DOI: 10.1158/1078-0432.CCR-08-1144. PMID: 19047099. 
  • X. Wang, L. Si, J. Guo. Treatment algorithm of metastatic mucosal melanoma.. „Chinese Clinical Oncology”. 3 (3), s. 38, Sep 2014. DOI: 10.3978/j.issn.2304-3865.2014.08.04. PMID: 25841464. 
  • S.N. Markovic, V.J. Suman, J.N. Ingle, J.S. Kaur i inni. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. „American Journal of Clinical Oncology”. 29 (4), s. 352–360, Aug 2006. DOI: 10.1097/01.coc.0000217877.78473.a4. PMID: 16891861. 
  • L. Si, X. Xu, Y. Kong, K.T. Flaherty i inni. Major response to everolimus in melanoma with acquired imatinib resistance. „J Clin Oncol”. 30 (4), s. e37-40, Feb 2012. DOI: 10.1200/JCO.2011.37.9644. PMID: 22162580. 
  • Edward P. Cawley. Genetic aspects of malignant melanoma. „AMA Arch Derm Syphilol.”, 1952. DOI: 10.1001/archderm.1952.01530230064006.. 

dx.doi.org

  • Vito W. Rebecca, Vernon K. Sondak, Keiran S.M. Smalley, A brief history of melanoma: from mummies to mutations, „Melanoma Res”, 22 (2), 2012, s. 114–22, DOI: 10.1097/CMR.0b013e328351fa4d, PMID: 22395415, PMCID: PMC3303163.
  • Arvin S. Yang, Paul B. Chapman, The history and future of chemotherapy for melanoma, „Hematology/Oncology Clinics of North America”, 23 (3), 2009, 583-97, x, DOI: 10.1016/j.hoc.2009.03.006, PMID: 19464604, PMCID: PMC3904102.

globenewswire.com

google.pl

books.google.pl

mayoclinic.org

miroslawstraczynski.pl

mp.pl

nature.com

nejm.org

nih.gov

ncbi.nlm.nih.gov

  • A.G. Goodson, D. Grossman. Strategies for early melanoma detection: Approaches to the patient with nevi. „Journal of the American Academy of Dermatology”. 60 (5), s. 719-735; quiz 736-8, May 2009. DOI: 10.1016/j.jaad.2008.10.065. PMID: 19389517. 
  • H. Tsao, C. Bevona, W. Goggins, T. Quinn. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. „Archives of dermatology”. 139 (3), s. 282–288, Mar 2003. PMID: 12622618. 
  • U. Kellner, N. Bornfeld, M.H. Foerster. Severe course of cutaneous melanoma associated paraneoplastic retinopathy. „British Journal of Ophthalmology”. 79 (8), s. 746–752, Aug 1995. PMID: 7547786. 
  • A.I. Riker, N. Zea, T. Trinh. The epidemiology, prevention, and detection of melanoma. „The Ochsner Journal”. 10 (2), s. 56–65, 2010. PMID: 21603359. 
  • D.S. Rigel. Epidemiology of melanoma. „Semin Cutan Med Surg”. 29 (4), s. 204–209, Dec 2010. DOI: 10.1016/j.sder.2010.10.005. PMID: 21277533. 
  • M. Berwick, E. Erdei, J. Hay. Melanoma epidemiology and public health. „Dermatol Clin”. 27 (2), s. 205-214, viii, Apr 2009. DOI: 10.1016/j.det.2008.12.002. PMID: 19254665. 
  • R.M. MacKie, A. Hauschild, A.M. Eggermont. Epidemiology of invasive cutaneous melanoma. „Ann Oncol”. 20 Suppl 6, s. vi1-7, Aug 2009. DOI: 10.1093/annonc/mdp252. PMID: 19617292. 
  • C.A. Fink, M.N. Bates. Melanoma and ionizing radiation: is there a causal relationship?. „Journal of Radiation Research”. 164 (5), s. 701–710, Nov 2005. PMID: 16238450. 
  • F.R. de Gruijl, H.J. Sterenborg, P.D. Forbes, R.E. Davies i inni. Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. „Cancer Research”. 53 (1), s. 53–60, Jan 1993. PMID: 8416751. 
  • T.R. Fears, C.C. Bird, D. Guerry, R.W. Sagebiel i inni. Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. „Cancer Research”. 62 (14), s. 3992–3996, Jul 2002. PMID: 12124332. 
  • J.M. Elwood, R.P. Gallagher. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. „International Journal of Cancer”. 78 (3), s. 276–280, Oct 1998. DOI: <276::AID-IJC2>3.0.CO;2-S 10.1002/(SICI)1097-0215(19981029)78:3<276::AID-IJC2>3.0.CO;2-S. PMID: 9766557. 
  • P. Autier, J.F. Doré. Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. „International Journal of Cancer”. 77 (4), s. 533–537, Aug 1998. PMID: 9679754. 
  • K.E. Johnson, B.C. Wulff, T.M. Oberyszyn, T.A. Wilgus. Ultraviolet light exposure stimulates HMGB1 release by keratinocytes. „Archives of Dermatological Research”. 305 (9), s. 805–815, Nov 2013. DOI: 10.1007/s00403-013-1401-2. PMID: 23942756. 
  • A.J. Dobson, S.R. Leeder. Mortality from malignant melanoma in Australia: effects due to country of birth. „International Journal of Epidemiology”. 11 (3), s. 207–211, Sep 1982. PMID: 7129734. 
  • S. Gandini, F. Sera, M.S. Cattaruzza, P. Pasquini i inni. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. „European Journal of Cancer”. 41 (1), s. 45–60, Jan 2005. DOI: 10.1016/j.ejca.2004.10.016. PMID: 15617990. 
  • R.P. Gallagher, J.J. Spinelli, T.K. Lee. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. „Cancer Epidemiol Biomarkers Prev”. 14 (3), s. 562–566, Mar 2005. DOI: 10.1158/1055-9965.EPI-04-0564. PMID: 15767329. 
  • J.H. Silva, B.C. Sá, A.L. Avila, G. Landman i inni. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. „Clinics (Sao Paulo)”. 66 (3), s. 493–499, 2011. PMID: 21552679. 
  • T.M. Skender-Kalnenas, D.R. English, P.J. Heenan. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?. „J Am Acad Dermatol”. 33 (6), s. 1000–1007, Dec 1995. PMID: 7490345. 
  • D. Massi, P. Carli, A. Franchi, M. Santucci. Naevus-associated melanomas: cause or chance?. „Melanoma Res”. 9 (1), s. 85–91, Feb 1999. PMID: 10338338. 
  • W.H. Clark, D.E. Elder, D. Guerry, M.N. Epstein i inni. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. „Hum Pathol”. 15 (12), s. 1147–1165, Dec 1984. PMID: 6500548. 
  • A.K. Rustgi. Familial pancreatic cancer: genetic advances. „Genes & Development”. 28 (1), s. 1–7, Jan 2014. DOI: 10.1101/gad.228452.113. PMID: 24395243. 
  • H.T. Lynch, R.E. Brand, D. Hogg, C.A. Deters i inni. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. „Cancer”. 94 (1), s. 84–96, Jan 2002. PMID: 11815963. 
  • C.B. Begg, I. Orlow, A.J. Hummer, B.K. Armstrong i inni. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. „J Natl Cancer Inst”. 97 (20), s. 1507–1515, Oct 2005. DOI: 10.1093/jnci/dji312. PMID: 16234564. 
  • S. Raimondi, F. Sera, S. Gandini, S. Iodice i inni. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. „Int J Cancer”. 122 (12), s. 2753–2760, Jun 2008. DOI: 10.1002/ijc.23396. PMID: 18366057. 
  • D. Zhang, C. Chen, X. Fu, S. Gu i inni. A meta-analysis of DNA repair gene XPC polymorphisms and cancer risk. „J Hum Genet”. 53 (1), s. 18–33, 2008. DOI: 10.1007/s10038-007-0215-5. PMID: 18097734. 
  • S. Blankenburg, I.R. König, R. Moessner, P. Laspe i inni. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. „Carcinogenesis”. 26 (6), s. 1085–1090, Jun 2005. DOI: 10.1093/carcin/bgi055. PMID: 15731165. 
  • R.C. Millikan, A. Hummer, C. Begg, J. Player i inni. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. „Carcinogenesis”. 27 (3), s. 610–618, Mar 2006. DOI: 10.1093/carcin/bgi252. PMID: 16258177. 
  • J. Han, G.A. Colditz, J.S. Liu, D.J. Hunter. Genetic variation in XPD, sun exposure, and risk of skin cancer. „Cancer Epidemiol Biomarkers Prev”. 14 (6), s. 1539–1544, Jun 2005. DOI: 10.1158/1055-9965.EPI-04-0846. PMID: 15941969. 
  • T. Debniak, R.J. Scott, B. Górski, C. Cybulski i inni. Common variants of DNA repair genes and malignant melanoma. „Eur J Cancer”. 44 (1), s. 110–114, Jan 2008. DOI: 10.1016/j.ejca.2007.10.006. PMID: 18024013. 
  • C. Li, Z. Liu, L.E. Wang, J.E. Gershenwald i inni. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. „Int J Cancer”. 122 (9), s. 2077–2084, May 2008. DOI: 10.1002/ijc.23357. PMID: 18183598. 
  • F.J. Moloney, H. Comber, P. O’Lorcain, P. O’Kelly i inni. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. „Br J Dermatol”. 154 (3), s. 498–504, Mar 2006. DOI: 10.1111/j.1365-2133.2005.07021.x. PMID: 16445782. 
  • G. Chaidemenos, A. Stratigos, M. Papakonstantinou, F. Tsatsou. Prevention of malignant melanoma. „Hippokratia”. 12 (1), s. 17–21, Jan 2008. PMID: 18923759. 
  • H. Vainio, A.B. Miller, F. Bianchini. An international evaluation of the cancer-preventive potential of sunscreens. „Int J Cancer”. 88 (5), s. 838–842, Dec 2000. PMID: 11072258. 
  • M.P. Purdue, L. From, B.K. Armstrong, A. Kricker i inni. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. „Cancer Epidemiol Biomarkers Prev”. 14 (8), s. 2015–2022, Aug 2005. DOI: 10.1158/1055-9965.EPI-05-0097. PMID: 16103454. 
  • L.K. Dennis, L.E. Beane Freeman, M.J. VanBeek. Sunscreen use and the risk for melanoma: a quantitative review. „Ann Intern Med”. 139 (12), s. 966–978, Dec 2003. PMID: 14678916. 
  • B.L. Diffey. Sunscreens and melanoma: the future looks bright. „Br J Dermatol”. 153 (2), s. 378–381, Aug 2005. DOI: 10.1111/j.1365-2133.2005.06729.x. PMID: 16086753. 
  • V.R. Doherty, R.M. MacKie. Reasons for poor prognosis in British patients with cutaneous malignant melanoma. „Br Med J (Clin Res Ed)”. 292 (6526), s. 987–989, Apr 1986. PMID: 3083979. 
  • N. Calonge, D.B. Petitti, T.G. DeWitt, L. Gordis i inni. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. „Ann Intern Med”. 150 (3), s. 188–193, Feb 2009. PMID: 19189908. 
  • J.F. Aitken, P.H. Youl, M. Janda, J.B. Lowe i inni. Increase in skin cancer screening during a community-based randomized intervention trial. „Int J Cancer”. 118 (4), s. 1010–1016, Feb 2006. DOI: 10.1002/ijc.21455. PMID: 16152577. 
  • J.F. Aitken, J.M. Elwood, J.B. Lowe, D.W. Firman i inni. A randomised trial of population screening for melanoma. „J Med Screen”. 9 (1), s. 33–37, 2002. PMID: 11943795. 
  • B. Krone, K.F. Kölmel, J.M. Grange, G. Mastrangelo i inni. Impact of vaccinations and infectious diseases on the risk of melanoma - evaluation of an EORTC case-control study. „Eur J Cancer”. 39 (16), s. 2372–2378, Nov 2003. PMID: 14556930. 
  • A. Pfahlberg, K.F. Kölmel, J.M. Grange, G. Mastrangelo i inni. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. „J Invest Dermatol”. 119 (3), s. 570–575, Sep 2002. DOI: 10.1046/j.1523-1747.2002.00643.x. PMID: 12230497. 
  • K.F. Kölmel, J.M. Grange, B. Krone, G. Mastrangelo i inni. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. „Eur J Cancer”. 41 (1), s. 118–125, Jan 2005. DOI: 10.1016/j.ejca.2004.09.023. PMID: 15617996. 
  • B. Krone, K.F. Kölmel, B.M. Henz, J.M. Grange. Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. „Eur J Cancer”. 41 (1), s. 104–117, Jan 2005. DOI: 10.1016/j.ejca.2004.08.010. PMID: 15617995. 
  • D.M. Parkin, F. Bray, J. Ferlay, P. Pisani. Estimating the world cancer burden: Globocan 2000. „Int J Cancer”. 94 (2), s. 153–156, Oct 2001. PMID: 11668491. 
  • R. Böni, C. Schuster, B. Nehrhoff, G. Burg. Epidemiology of skin cancer. „Neuro Endocrinol Lett”. 23 Suppl 2, s. 48–51, Jul 2002. PMID: 12163848. 
  • E. Erdei, S.M. Torres. A new understanding in the epidemiology of melanoma. „Expert Rev Anticancer Ther”. 10 (11), s. 1811–1823, Nov 2010. DOI: 10.1586/era.10.170. PMID: 21080806. 
  • H.S. Greenwald, E.B. Friedman, I. Osman. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. „Melanoma Res”. 22 (1), s. 1–8, Feb 2012. DOI: 10.1097/CMR.0b013e32834e6aa0. PMID: 22108608. 
  • B.G. Goldstein, A.O. Goldstein. Diagnosis and management of malignant melanoma. „Am Fam Physician”. 63 (7), s. 1359–1368, 1374, Apr 2001. PMID: 11310650. 
  • G. Palmieri, M. Capone, M.L. Ascierto, G. Gentilcore i inni. Main roads to melanoma. „Journal of Translational Medicine”. 7, s. 86, 2009. DOI: 10.1186/1479-5876-7-86. PMID: 19828018. 
  • E. Shtivelman, M.Q. Davies, P. Hwu, J. Yang i inni. Pathways and therapeutic targets in melanoma. „Oncotarget”. 5 (7), s. 1701–1752, Apr 2014. PMID: 24743024. 
  • C. Bertolotto. Melanoma: from melanocyte to genetic alterations and clinical options. „Scientifica (Cairo)”. 2013, s. 635203, 2013. DOI: 10.1155/2013/635203. PMID: 24416617. 
  • M. Takata, H. Murata, T. Saida. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. „Pigment Cell & Melanoma Research”. 23 (1), s. 64–71, Feb 2010. DOI: 10.1111/j.1755-148X.2009.00645.x. PMID: 19788535. 
  • H. Tsao, L. Chin, L.A. Garraway, D.E. Fisher. Melanoma: from mutations to medicine. „Genes & Development”. 26 (11), s. 1131–1155, Jun 2012. DOI: 10.1101/gad.191999.112. PMID: 22661227. 
  • J.M. Mehnert, H.M. Kluger. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. „Curr Oncol Rep”. 14 (5), s. 449–457, Oct 2012. DOI: 10.1007/s11912-012-0249-5. PMID: 22723080. 
  • L. Mervic. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. „PLoS One”. 7 (3), s. e32955, 2012. DOI: 10.1371/journal.pone.0032955. PMID: 22412958. 
  • F. Tas. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. „Journal of Oncology”. 2012, s. 647684, 2012. DOI: 10.1155/2012/647684. PMID: 22792102. 
  • F. Meier, S. Will, U. Ellwanger, B. Schlagenhauff i inni. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. „Br J Dermatol”. 147 (1), s. 62–70, Jul 2002. PMID: 12100186. 
  • A. Kardynal, M. Olszewska. Modern non-invasive diagnostic techniques in the detection of early cutaneous melanoma. „J Dermatol Case Rep”. 8 (1), s. 1–8, Mar 2014. DOI: 10.3315/jdcr.2014.1161. PMID: 24748903. 
  • A. Blum, R. Hofmann-Wellenhof, H. Luedtke, U. Ellwanger i inni. Value of the clinical history for different users of dermoscopy compared with results of digital image analysis. „Journal of the European Academy of Dermatology”. 18 (6), s. 665–669, Nov 2004. DOI: 10.1111/j.1468-3083.2004.01044.x. PMID: 15482291. 
  • I. Tromme, L. Sacré, F. Hammouch, C. Legrand i inni. Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: results from an observational study. „British Journal of Dermatology”. 167 (4), s. 778–786, Oct 2012. DOI: 10.1111/j.1365-2133.2012.11042.x. PMID: 22564185. 
  • C. Longo, F. Farnetani, S. Ciardo, A.M. Cesinaro i inni. Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study of 140 cases. „British Journal of Dermatology”. 169 (1), s. 58–67, Jul 2013. DOI: 10.1111/bjd.12259. PMID: 23374159. 
  • E. Szymańska, M. Maj, M. Majsterek, J. Litniewski i inni. The usefulness of high frequency ultrasonography in dermatological practice-ultrasound features of selected cutaneous lesions. „Polski Merkuriusz Lekarski”. 31 (181), s. 37–40, Jul 2011. PMID: 21870707. 
  • D. Jasaitiene, S. Valiukeviciene, G. Linkeviciute, R. Raisutis i inni. Principles of high-frequency ultrasonography for investigation of skin pathology. „Journal of European Academy of Dermatology and Venereology”. 25 (4), s. 375–382, Apr 2011. DOI: 10.1111/j.1468-3083.2010.03837.x. PMID: 20849441. 
  • P. Mohr, A.M. Eggermont, A. Hauschild, A. Buzaid. Staging of cutaneous melanoma. „Annals of Oncology”. 20 Suppl 6, s. vi14-21, Aug 2009. DOI: 10.1093/annonc/mdp256. PMID: 19617293. 
  • W.D. Holder, R.L. White, J.H. Zuger, E.J. Easton i inni. Effectiveness of positron emission tomography for the detection of melanoma metastases. „Ann Surg”. 227 (5), s. 764-769; discussion 769-71, May 1998. PMID: 9605668. 
  • D. Rinne, R.P. Baum, G. Hör, R. Kaufmann. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. „Cancer”. 82 (9), s. 1664–1671, May 1998. PMID: 9576286. 
  • H.C. Steinert, R.A. Huch Böni, A. Buck, R. Böni i inni. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. „Radiology”. 195 (3), s. 705–709, Jun 1995. DOI: 10.1148/radiology.195.3.7753998. PMID: 7753998. 
  • S.M. Swetter, L.A. Carroll, D.L. Johnson, G.M. Segall. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. „Annals of Surgery Oncol”. 9 (7), s. 646–653, Aug 2002. PMID: 12167578. 
  • H.E. Daldrup-Link, C. Franzius, T.M. Link, D. Laukamp i inni. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. „American Journal of Roentgenology”. 177 (1), s. 229–236, Jul 2001. DOI: 10.2214/ajr.177.1.1770229. PMID: 11418435. 
  • A. Aydin, J.Q. Yu, H. Zhuang, A. Alavi. Detection of bone marrow metastases by FDG-PET and missed by bone scintigraphy in widespread melanoma. „Clin Nucl Med”. 30 (9), s. 606–607, Sep 2005. PMID: 16100478. 
  • L. Schuchter, D.J. Schultz, M. Synnestvedt, B.J. Trock i inni. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. „Ann Intern Med”. 125 (5), s. 369–375, Sep 1996. PMID: 8702087. 
  • C.M. Balch, S.J. Soong, J.E. Gershenwald, J.F. Thompson i inni. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. „Journal of Clinical Oncology”. 19 (16), s. 3622–3634, Aug 2001. PMID: 11504744. 
  • J. Homsi, M. Kashani-Sabet, J.L. Messina, A. Daud. Cutaneous melanoma: prognostic factors. „Cancer Control”. 12 (4), s. 223–229, Oct 2005. PMID: 16258493. 
  • C. Garbe, P. Büttner, J. Bertz, G. Burg i inni. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. „Cancer”. 75 (10), s. 2484–2491, May 1995. PMID: 7736392. 
  • A. Breslow. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. „Annals of Surgery”. 172 (5), s. 902–908, Nov 1970. PMID: 5477666. 
  • E. Nagore, V. Oliver, R. Botella-Estrada, S. Moreno-Picot i inni. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. „Melanoma Res”. 15 (3), s. 169–177, Jun 2005. PMID: 15917698. 
  • S.B. Kesmodel, G.C. Karakousis, J.D. Botbyl, R.J. Canter i inni. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. „Annals of Surgical Oncology”. 12 (6), s. 449–458, Jun 2005. DOI: 10.1245/ASO.2005.04.027. PMID: 15864482. 
  • S.C. Paek, K.A. Griffith, T.M. Johnson, V.K. Sondak i inni. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. „Cancer”. 109 (1), s. 100–108, Jan 2007. DOI: 10.1002/cncr.22382. PMID: 17146784. 
  • V.K. Sondak, J.M. Taylor, M.S. Sabel, Y. Wang i inni. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. „Ann Surg Oncol”. 11 (3), s. 247–258, Mar 2004. PMID: 14993019. 
  • W.H. Clark, D.E. Elder, D. Guerry, L.E. Braitman i inni. Model predicting survival in stage I melanoma based on tumor progression. „J Natl Cancer Inst”. 81 (24), s. 1893–1904, Dec 1989. PMID: 2593166. 
  • V.J. McGovern, H.M. Shaw, G.W. Milton. Prognosis in patients with thin malignant melanoma: influence of regression. „Histopathology”. 7 (5), s. 673–680, Sep 1983. PMID: 6629343. 
  • U. Veronesi, N. Cascinelli. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. „Arch Surg”. 126 (4), s. 438–441, Apr 1991. PMID: 2009058. 
  • U. Veronesi, N. Cascinelli, J. Adamus, C. Balch i inni. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. „N Engl J Med”. 318 (18), s. 1159–1162, May 1988. DOI: 10.1056/NEJM198805053181804. PMID: 3079582. 
  • C.M. Balch, S.J. Soong, T. Smith, M.I. Ross i inni. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. „Ann Surg Oncol”. 8 (2), s. 101–108, Mar 2001. PMID: 11258773. 
  • C.M. Balch, M.M. Urist, C.P. Karakousis, T.J. Smith i inni. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. „Ann Surg”. 218 (3), s. 262-267; discussion 267-9, Sep 1993. PMID: 8373269. 
  • J.M. Thomas, J. Newton-Bishop, R. A’Hern, G. Coombes i inni. Excision margins in high-risk malignant melanoma. „N Engl J Med”. 350 (8), s. 757–766, Feb 2004. DOI: 10.1056/NEJMoa030681. PMID: 14973217. 
  • P.I. Haigh, L.A. DiFronzo, D.R. McCready. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. „Can J Surg”. 46 (6), s. 419–426, Dec 2003. PMID: 14680348. 
  • J.H. Kunishige, D.G. Brodland, J.A. Zitelli. Surgical margins for melanoma in situ. „J Am Acad Dermatol”. 66 (3), s. 438–444, Mar 2012. DOI: 10.1016/j.jaad.2011.06.019. PMID: 22196979. 
  • F. Amersi, D.L. Morton. The role of sentinel lymph node biopsy in the management of melanoma. „Adv Surg”. 41, s. 241–256, 2007. PMID: 17972569. 
  • D.L. Morton, J.F. Thompson, A.J. Cochran, N. Mozzillo i inni. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. „N Engl J Med”. 370 (7), s. 599–609, Feb 2014. DOI: 10.1056/NEJMoa1310460. PMID: 24521106. 
  • R.H. Andtbacka, J.E. Gershenwald. Role of sentinel lymph node biopsy in patients with thin melanoma. „J Natl Compr Canc Netw”. 7 (3), s. 308–317, Mar 2009. PMID: 19401063. 
  • C. Mitteldorf, H.P. Bertsch, K. Jung, K.M. Thoms i inni. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. „Ann Surg Oncol”. 21 (7), s. 2252–2258, Jul 2014. DOI: 10.1245/s10434-014-3641-6. PMID: 24652352. 
  • S.L. Wong, C.M. Balch, P. Hurley, S.S. Agarwala i inni. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. „J Clin Oncol”. 30 (23), s. 2912–2918, Aug 2012. DOI: 10.1200/JCO.2011.40.3519. PMID: 22778321. 
  • N. Cascinelli, E. Bombardieri, R. Bufalino, T. Camerini i inni. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. „J Clin Oncol”. 24 (27), s. 4464–4471, Sep 2006. DOI: 10.1200/JCO.2006.06.3198. PMID: 16983115. 
  • J.H. Lee, R. Essner, H. Torisu-Itakura, L. Wanek i inni. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. „J Clin Oncol”. 22 (18), s. 3677–3684, Sep 2004. DOI: 10.1200/JCO.2004.01.012. PMID: 15365064. 
  • J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith i inni. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. „J Clin Oncol”. 14 (1), s. 7–17, Jan 1996. PMID: 8558223. 
  • R.F. Kefford. Adjuvant therapy of cutaneous melanoma: the interferon debate. „Ann Oncol”. 14 (3), s. 358–365, Mar 2003. PMID: 12598338. 
  • D.G. Varma, W.R. Richli, C. Charnsangavej, B.I. Samuels i inni. MR appearance of the distended iliopsoas bursa. „AJR Am J Roentgenol”. 156 (5), s. 1025–1028, May 1991. DOI: 10.2214/ajr.156.5.2017926. PMID: 2017926. 
  • A.M. Eggermont, S. Suciu, M. Santinami, A. Testori i inni. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. „Lancet”. 372 (9633), s. 117–126, Jul 2008. DOI: 10.1016/S0140-6736(08)61033-8. PMID: 18620949. 
  • J.Y. Chen, G. Hruby, R.A. Scolyer, R. Murali i inni. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. „Cancer”. 113 (10), s. 2770–2778, Nov 2008. DOI: 10.1002/cncr.23895. PMID: 18823042. 
  • S. Agrawal, J.M. Kane, B.A. Guadagnolo, W.G. Kraybill i inni. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. „Cancer”. 115 (24), s. 5836–5844, Dec 2009. DOI: 10.1002/cncr.24627. PMID: 19701906. 
  • B. Zbytek, J.A. Carlson, J. Granese, J. Ross i inni. Current concepts of metastasis in melanoma. „Expert Rev Dermatol”. 3 (5), s. 569–585, Oct 2008. DOI: 10.1586/17469872.3.5.569. PMID: 19649148. 
  • J.F. Thompson, P.C. Kam. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. „J Surg Oncol”. 88 (1), s. 1–3, Oct 2004. DOI: 10.1002/jso.20112. PMID: 15384062. 
  • G.M. Beasley, A. Caudle, R.P. Petersen, N.S. McMahon i inni. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. „J Am Coll Surg”. 208 (5), s. 706-715; discussion 715-7, May 2009. DOI: 10.1016/j.jamcollsurg.2008.12.019. PMID: 19476821. 
  • C.E. Boesch, T. Meyer, L. Waschke, S. Merkel i inni. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. „Int J Hyperthermia”. 26 (1), s. 16–20, Feb 2010. DOI: 10.3109/02656730903236086. PMID: 20100048. 
  • S. Bhatia, S.S. Tykodi, S.M. Lee, J.A. Thompson. Systemic therapy of metastatic melanoma: on the road to cure. „Oncology (Williston Park)”. 29 (2), s. 126–135, Feb 2015. PMID: 25683834. 
  • F. Spagnolo, P. Ghiorzo, L. Orgiano, L. Pastorino i inni. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. „Onco Targets Ther”. 8, s. 157–168, 2015. DOI: 10.2147/OTT.S39096. PMID: 25653539. 
  • P.A. Ascierto, J.M. Kirkwood, J.J. Grob, E. Simeone i inni. The role of BRAF V600 mutation in melanoma. „J Transl Med”. 10, s. 85, 2012. DOI: 10.1186/1479-5876-10-85. PMID: 22554099. 
  • H.C. Tang, Y.C. Chen. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. „Int J Nanomedicine”. 10, s. 3131–3146, 2015. DOI: 10.2147/IJN.S80150. PMID: 25960652. 
  • J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel i inni. Distinct sets of genetic alterations in melanoma. „N Engl J Med”. 353 (20), s. 2135–2147, Nov 2005. DOI: 10.1056/NEJMoa050092. PMID: 16291983. 
  • K.M. Ilieva, I. Correa, D.H. Josephs, P. Karagiannis i inni. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. „Mol Cancer Ther”. 13 (12), s. 2769–2783, Dec 2014. DOI: 10.1158/1535-7163.MCT-14-0290. PMID: 25385327. 
  • A.M. Menzies, G.V. Long, R. Murali. Dabrafenib and its potential for the treatment of metastatic melanoma. „Drug Des Devel Ther”. 6, s. 391–405, 2012. DOI: 10.2147/DDDT.S38998. PMID: 23251089. 
  • J. Wheler, R. Yelensky, G. Falchook, K.B. Kim i inni. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. „BMC Cancer”. 15, s. 61, 2015. DOI: 10.1186/s12885-015-1029-z. PMID: 25886620. 
  • C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski i inni. Improved overall survival in melanoma with combined dabrafenib and trametinib. „N Engl J Med”. 372 (1), s. 30–39, Jan 2015. DOI: 10.1056/NEJMoa1412690. PMID: 25399551. 
  • G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko i inni. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. „N Engl J Med”. 371 (20), s. 1877–1888, Nov 2014. DOI: 10.1056/NEJMoa1406037. PMID: 25265492. 
  • M.M. Chan, L.E. Haydu, A.M. Menzies, M.W. Azer i inni. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. „Cancer”. 120 (20), s. 3142–3153, Oct 2014. DOI: 10.1002/cncr.28851. PMID: 24985732. 
  • M.S. Carlino, K. Gowrishankar, C.A. Saunders, G.M. Pupo i inni. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. „Mol Cancer Ther”. 12 (7), s. 1332–1342, Jul 2013. DOI: 10.1158/1535-7163.MCT-13-0011. PMID: 23645591. 
  • A. Niezgoda, P. Niezgoda, R. Czajkowski. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. „Biomed Res Int”. 2015, s. 851387, 2015. DOI: 10.1155/2015/851387. PMID: 26171394. 
  • J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez i inni. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. „N Engl J Med”. 366 (8), s. 707–714, Feb 2012. DOI: 10.1056/NEJMoa1112302. PMID: 22356324. 
  • A. Swaika, J.A. Crozier, R.W. Joseph. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. „Drug Des Devel Ther”. 8, s. 775–787, 2014. DOI: 10.2147/DDDT.S31143. PMID: 24966667. 
  • P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen i inni. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. „N Engl J Med”. 364 (26), s. 2507–2516, Jun 2011. DOI: 10.1056/NEJMoa1103782. PMID: 21639808. 
  • P.A. Ascierto, D. Minor, A. Ribas, C. Lebbe i inni. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. „J Clin Oncol”. 31 (26), s. 3205–3211, Sep 2013. DOI: 10.1200/JCO.2013.49.8691. PMID: 23918947. 
  • K.T. Flaherty, C. Robert, P. Hersey, P. Nathan i inni. Improved survival with MEK inhibition in BRAF-mutated melanoma. „N Engl J Med”. 367 (2), s. 107–114, Jul 2012. DOI: 10.1056/NEJMoa1203421. PMID: 22663011. 
  • C. Robert, R. Dummer, R. Gutzmer, P. Lorigan i inni. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. „Lancet Oncol”. 14 (8), s. 733–740, Jul 2013. DOI: 10.1016/S1470-2045(13)70237-7. PMID: 23735514. 
  • I.C. Glitza, M.A. Davies. Genotyping of cutaneous melanoma. „Chin Clin Oncol”. 3 (3), s. 27, Sep 2014. DOI: 10.3978/j.issn.2304-3865.2014.03.01. PMID: 25632386. 
  • M.S. Carlino, J.R. Todd, H. Rizos. Resistance to c-Kit inhibitors in melanoma: insights for future therapies. „Oncoscience”. 1 (6), s. 423–426, 2014. PMID: 25594040. 
  • J. Guo, L. Si, Y. Kong, K.T. Flaherty i inni. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. „J Clin Oncol”. 29 (21), s. 2904–2909, Jul 2011. DOI: 10.1200/JCO.2010.33.9275. PMID: 21690468. 
  • D.M. Pardoll. The blockade of immune checkpoints in cancer immunotherapy. „Nat Rev Cancer”. 12 (4), s. 252–264, Apr 2012. DOI: 10.1038/nrc3239. PMID: 22437870. 
  • M.A. Postow, M.K. Callahan, J.D. Wolchok. Immune Checkpoint Blockade in Cancer Therapy. „J Clin Oncol”. 33 (17), s. 1974–1982, Jun 2015. DOI: 10.1200/JCO.2014.59.4358. PMID: 25605845. 
  • J.J. Luke, P.A. Ott. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. „Oncotarget”. 6 (6), s. 3479–3492, Feb 2015. PMID: 25682878. 
  • M. Atefi, E. Avramis, A. Lassen, D.J. Wong i inni. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. „Clin Cancer Res”. 20 (13), s. 3446–3457, Jul 2014. DOI: 10.1158/1078-0432.CCR-13-2797. PMID: 24812408. 
  • B. Homet Moreno, A. Ribas. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. „Br J Cancer”. 112 (9), s. 1421–1427, Apr 2015. DOI: 10.1038/bjc.2015.124. PMID: 25856776. 
  • O. Hamid, C. Robert, A. Daud, F.S. Hodi i inni. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. „N Engl J Med”. 369 (2), s. 134–144, Jul 2013. DOI: 10.1056/NEJMoa1305133. PMID: 23724846. 
  • T.C. Gangadhar, A.K. Salama. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. „Onco Targets Ther”. 8, s. 929–937, 2015. DOI: 10.2147/OTT.S53164. PMID: 25960664. 
  • A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf i inni. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. „Lancet Oncol”, Jun 2015. DOI: 10.1016/S1470-2045(15)00083-2. PMID: 26115796. 
  • S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger i inni. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. „N Engl J Med”. 366 (26), s. 2443–2454, Jun 2012. DOI: 10.1056/NEJMoa1200690. PMID: 22658127. 
  • S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger i inni. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. „J Clin Oncol”. 32 (10), s. 1020–1030, Apr 2014. DOI: 10.1200/JCO.2013.53.0105. PMID: 24590637. 
  • C. Robert, G.V. Long, B. Brady, C. Dutriaux i inni. Nivolumab in previously untreated melanoma without BRAF mutation. „N Engl J Med”. 372 (4), s. 320–330, Jan 2015. DOI: 10.1056/NEJMoa1412082. PMID: 25399552. 
  • J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow i inni. Nivolumab plus ipilimumab in advanced melanoma. „N Engl J Med”. 369 (2), s. 122–133, Jul 2013. DOI: 10.1056/NEJMoa1302369. PMID: 23724867. 
  • C. Nakaseko, S. Miyatake, T. Iida, S. Hara i inni. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail. „J Exp Med”. 190 (6), s. 765–774, Sep 1999. PMID: 10499915. 
  • R.J. Greenwald, M.A. Oosterwegel, D. van der Woude, A. Kubal i inni. CTLA-4 regulates cell cycle progression during a primary immune response. „Eur J Immunol”. 32 (2), s. 366–373, Feb 2002. DOI: 10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5. PMID: 11807776. 
  • L.H. Camacho. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. „Cancer Med”. 4 (5), s. 661–672, May 2015. DOI: 10.1002/cam4.371. PMID: 25619164. 
  • A. Ito, S. Kondo, K. Tada, S. Kitano. Clinical Development of Immune Checkpoint Inhibitors. „Biomed Res Int”. 2015, s. 605478, 2015. DOI: 10.1155/2015/605478. PMID: 26161407. 
  • F.S. Hodi, S.J. O’Day, D.F. McDermott, R.W. Weber i inni. Improved survival with ipilimumab in patients with metastatic melanoma. „N Engl J Med”. 363 (8), s. 711–723, Aug 2010. DOI: 10.1056/NEJMoa1003466. PMID: 20525992. 
  • C. Robert, L. Thomas, I. Bondarenko, S. O’Day i inni. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. „N Engl J Med”. 364 (26), s. 2517–2526, Jun 2011. DOI: 10.1056/NEJMoa1104621. PMID: 21639810. 
  • D. Schadendorf, F.S. Hodi, C. Robert, J.S. Weber i inni. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. „J Clin Oncol”. 33 (17), s. 1889–1894, Jun 2015. DOI: 10.1200/JCO.2014.56.2736. PMID: 25667295. 
  • A. Ribas, R. Kefford, M.A. Marshall, C.J. Punt i inni. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. „J Clin Oncol”. 31 (5), s. 616–622, Feb 2013. DOI: 10.1200/JCO.2012.44.6112. PMID: 23295794. 
  • S. Bhatia, S.S. Tykodi, J.A. Thompson. Treatment of metastatic melanoma: an overview. „Oncology (Williston Park)”. 23 (6), s. 488–496, May 2009. PMID: 19544689. 
  • M.C. Foletto, S.E. Haas. Cutaneous melanoma: new advances in treatment. „An Bras Dermatol”. 89 (2). s. 301–310. PMID: 24770508. 
  • M.B. Atkins, L. Kunkel, M. Sznol, S.A. Rosenberg. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. „Cancer J Sci Am”. 6 Suppl 1, s. S11-4, Feb 2000. PMID: 10685652. 
  • M.B. Atkins, M.T. Lotze, J.P. Dutcher, R.I. Fisher i inni. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. „J Clin Oncol”. 17 (7), s. 2105–2116, Jul 1999. PMID: 10561265. 
  • M.L. Ascierto, I. Melero, P.A. Ascierto. Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. „Front Oncol”. 5, s. 152, 2015. DOI: 10.3389/fonc.2015.00152. PMID: 26217587. 
  • P.A. Ascierto, F.M. Marincola, M.B. Atkins. What’s new in melanoma? Combination!. „J Transl Med”. 13, s. 213, 2015. DOI: 10.1186/s12967-015-0582-1. PMID: 26141621. 
  • J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob i inni. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. „N Engl J Med”. 373 (1), s. 23–34, Jul 2015. DOI: 10.1056/NEJMoa1504030. PMID: 26027431. 
  • A.Y. Bedikian, M. Millward, H. Pehamberger, R. Conry i inni. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. „J Clin Oncol”. 24 (29), s. 4738–4745, Oct 2006. DOI: 10.1200/JCO.2006.06.0483. PMID: 16966688. 
  • P. Lui, R. Cashin, M. Machado, M. Hemels i inni. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. „Cancer Treat Rev”. 33 (8), s. 665–680, Dec 2007. DOI: 10.1016/j.ctrv.2007.06.004. PMID: 17919823. 
  • M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck i inni. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. „J Clin Oncol”. 18 (1), s. 158–166, Jan 2000. PMID: 10623706. 
  • C.I. Falkson, J. Ibrahim, J.M. Kirkwood, A.S. Coates i inni. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. „J Clin Oncol”. 16 (5), s. 1743–1751, May 1998. PMID: 9586887. 
  • P.M. Patel, S. Suciu, L. Mortier, W.H. Kruit i inni. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). „Eur J Cancer”. 47 (10), s. 1476–1483, Jul 2011. DOI: 10.1016/j.ejca.2011.04.030. PMID: 21600759. 
  • S.S. Legha, S. Ring, A. Bedikian, C. Plager i inni. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. „Ann Oncol”. 7 (8), s. 827–835, Oct 1996. PMID: 8922197. 
  • M.B. Atkins, J.A. Gollob, J.A. Sosman, D.F. McDermott i inni. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. „Clin Cancer Res”. 8 (10), s. 3075–3081, Oct 2002. PMID: 12374674. 
  • P.H. Wiernik, A.I. Einzig. Taxol in malignant melanoma. „J Natl Cancer Inst Monogr”, s. 185–187, 1993. PMID: 7912525. 
  • R.D. Rao, S.G. Holtan, J.N. Ingle, G.A. Croghan i inni. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. „Cancer”. 106 (2), s. 375–382, Jan 2006. DOI: 10.1002/cncr.21611. PMID: 16342250. 
  • F.E. Nathan, D. Berd, T. Sato, M.J. Mastrangelo. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. „Cancer”. 88 (1), s. 79–87, Jan 2000. PMID: 10618609. 
  • A. Pflugfelder, T.K. Eigentler, U. Keim, B. Weide i inni. Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. „PLoS One”. 6 (2), s. e16882, 2011. DOI: 10.1371/journal.pone.0016882. PMID: 21359173. 
  • L.M. Evans, E.S. Casper, R. Rosenbluth. Phase II trial of carboplatin in advanced malignant melanoma. „Cancer Treat Rep”. 71 (2), s. 171–172, Feb 1987. PMID: 3542209. 
  • D. Khayat, B. Giroux, J. Berille, V. Cour i inni. Fotemustine in the treatment of brain primary tumors and metastases. „Cancer Invest”. 12 (4), s. 414–420, 1994. DOI: 10.3109/07357909409038234. PMID: 8032964. 
  • M.F. Avril, S. Aamdal, J.J. Grob, A. Hauschild i inni. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. „J Clin Oncol”. 22 (6), s. 1118–1125, Mar 2004. DOI: 10.1200/JCO.2004.04.165. PMID: 15020614. 
  • O. Eton, S.S. Legha, A.Y. Bedikian, J.J. Lee i inni. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. „J Clin Oncol”. 20 (8), s. 2045–2052, Apr 2002. PMID: 11956264. 
  • M.B. Atkins, J. Hsu, S. Lee, G.I. Cohen i inni. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. „J Clin Oncol”. 26 (35), s. 5748–5754, Dec 2008. DOI: 10.1200/JCO.2008.17.5448. PMID: 19001327. 
  • N.J. Ives, R.L. Stowe, P. Lorigan, K. Wheatley. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. „J Clin Oncol”. 25 (34), s. 5426–5434, Dec 2007. DOI: 10.1200/JCO.2007.12.0253. PMID: 18048825. 
  • E. Maverakis, L.A. Cornelius, G.M. Bowen, T. Phan i inni. Metastatic melanoma - a review of current and future treatment options. „Acta Dermato-Venereologica”. 95 (5), s. 516–524, May 2015. DOI: 10.2340/00015555-2035. PMID: 25520039. 
  • A.M. Leung, D.M. Hari, D.L. Morton. Surgery for distant melanoma metastasis. „The Cancer Journal”. 18 (2). s. 176–184. DOI: 10.1097/PPO.0b013e31824bc981. PMID: 22453019. 
  • D.W. Ollila, E.C. Hsueh, S.L. Stern, D.L. Morton. Metastasectomy for recurrent stage IV melanoma. „Journal of Surgical Oncology”. 71 (4), s. 209–213, Aug 1999. PMID: 10440757. 
  • P.V. Dickson, J.E. Gershenwald. Staging and prognosis of cutaneous melanoma. „Surgical Oncology Clinics of North America”. 20 (1), s. 1–17, Jan 2011. DOI: 10.1016/j.soc.2010.09.007. PMID: 21111956. 
  • C.C. McLaughlin, X.C. Wu, A. Jemal, H.J. Martin i inni. Incidence of noncutaneous melanomas in the U.S.. „Cancer”. 103 (5), s. 1000–1007, Mar 2005. DOI: 10.1002/cncr.20866. PMID: 15651058. 
  • M. Mihajlovic, S. Vlajkovic, P. Jovanovic, V. Stefanovic. Primary mucosal melanomas: a comprehensive review. „International Journal of Clinical and Experimental Pathology”. 5 (8), s. 739–753, 2012. PMID: 23071856. 
  • N. Seetharamu, P.A. Ott, A.C. Pavlick. Mucosal melanomas: a case-based review of the literature. „Oncologist”. 15 (7), s. 772–781, 2010. DOI: 10.1634/theoncologist.2010-0067. PMID: 20571149. 
  • P. Jovanovic, M. Mihajlovic, J. Djordjevic-Jocic, S. Vlajkovic i inni. Ocular melanoma: an overview of the current status. „International Journal of Clinical and Experimental Pathology”. 6 (7), s. 1230–1244, 2013. PMID: 23826405. 
  • B.E. Damato, S.E. Coupland. Ocular melanoma. „Saudi Journal of Ophthalmology”. 26 (2), s. 137–144, Apr 2012. DOI: 10.1016/j.sjopt.2012.02.004. PMID: 23960984. 
  • J.R. Wong, A.A. Nanji, A. Galor, C.L. Karp. Management of conjunctival malignant melanoma: a review and update. „Expert Review of Ophthalmology”. 9 (3), s. 185–204, Jun 2014. DOI: 10.1586/17469899.2014.921119. PMID: 25580155. 
  • P.R. Pereira, A.N. Odashiro, L.A. Lim, C. Miyamoto i inni. Current and emerging treatment options for uveal melanoma. „Journal of Clinical Ophthalmology”. 7, s. 1669–1682, 2013. DOI: 10.2147/OPTH.S28863. PMID: 24003303. 
  • I. Puusaari, J. Heikkonen, P. Summanen, A. Tarkkanen i inni. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. „Ophthalmology”. 110 (11), s. 2223–2234, Nov 2003. DOI: 10.1016/S0161-6420(03)00661-4. PMID: 14597534. 
  • B. Damato, I. Patel, I.R. Campbell, H.M. Mayles i inni. Local tumor control after 106Ru brachytherapy of choroidal melanoma. „International Journal of Radiation Oncology”. 63 (2), s. 385–391, Oct 2005. DOI: 10.1016/j.ijrobp.2005.02.017. PMID: 15913907. 
  • T.M. Aaberg, C.S. Bergstrom, Z.J. Hickner, M.J. Lynn. Long-term results of primary transpupillary thermal therapy for the treatment of choroidal malignant melanoma. „British Journal of Ophthalmology”. 92 (6), s. 741–746, Jun 2008. DOI: 10.1136/bjo.2007.132951. PMID: 18296506. 
  • J.W. Harbour, T.A. Meredith, P.A. Thompson, M.E. Gordon. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. „Ophthalmology”. 110 (11), s. 2207-2214; discussion 2215, Nov 2003. DOI: 10.1016/S0161-6420(03)00858-3. PMID: 14597531. 
  • C.L. Shields, J.A. Shields, N. Perez, A.D. Singh i inni. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. „Ophthalmology”. 109 (2), s. 225–234, Feb 2002. PMID: 11825800. 
  • A.A. Yarovoy, D.A. Magaramov, E.S. Bulgakova. The comparison of ruthenium brachytherapy and simultaneous transpupillary thermotherapy of choroidal melanoma with brachytherapy alone. „Brachytherapy”. 11 (3). s. 224–229. DOI: 10.1016/j.brachy.2011.09.007. PMID: 22104351. 
  • U.B. Hofmann, C.S. Kauczok-Vetter, R. Houben, J.C. Becker. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. „Clinical Cancer Research”. 15 (1), s. 324–329, Jan 2009. DOI: 10.1158/1078-0432.CCR-08-2243. PMID: 19118061. 
  • A. Calipel, S. Landreville, A. De La Fouchardière, F. Mascarelli i inni. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. „Clinical and Experimental Metastasis”. 31 (5), s. 553–564, Jun 2014. DOI: 10.1007/s10585-014-9649-2. PMID: 24652072. 
  • G.S. Falchook, K.D. Lewis, J.R. Infante, M.S. Gordon i inni. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. „The Lancet Oncology”. 13 (8), s. 782–789, Aug 2012. DOI: 10.1016/S1470-2045(12)70269-3. PMID: 22805292. 
  • J.M. Kirkwood, L. Bastholt, C. Robert, J. Sosman i inni. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. „Clinical Cancer Research”. 18 (2), s. 555–567, Jan 2012. DOI: 10.1158/1078-0432.CCR-11-1491. PMID: 22048237. 
  • R. Danielli, R. Ridolfi, V. Chiarion-Sileni, P. Queirolo i inni. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. „Cancer Immunol Immunother”. 61 (1), s. 41–48, Jan 2012. DOI: 10.1007/s00262-011-1089-0. PMID: 21833591. 
  • C. Wei, S. Sirikanjanapong, S. Lieberman, M. Delacure i inni. Primary mucosal melanoma arising from the eustachian tube with CTLA-4, IL-17A, IL-17C, and IL-17E upregulation. „Ear, Nose & Throat Journal”. 92 (1), s. 36–40, Jan 2013. PMID: 23354891. 
  • M. Del Vecchio, L. Di Guardo, P.A. Ascierto, A.M. Grimaldi i inni. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. „European Journal of Cancer”. 50 (1), s. 121–127, Jan 2014. DOI: 10.1016/j.ejca.2013.09.007. PMID: 24100024. 
  • J.A. Curtin, K. Busam, D. Pinkel, B.C. Bastian. Somatic activation of KIT in distinct subtypes of melanoma. „Journal of Clinical Oncology”. 24 (26), s. 4340–4346, Sep 2006. DOI: 10.1200/JCO.2006.06.2984. PMID: 16908931. 
  • F.S. Hodi, P. Friedlander, C.L. Corless, M.C. Heinrich i inni. Major response to imatinib mesylate in KIT-mutated melanoma. „Journal of Clinical Oncology”. 26 (12), s. 2046–2051, Apr 2008. DOI: 10.1200/JCO.2007.14.0707. PMID: 18421059. 
  • J. Lutzky, J. Bauer, B.C. Bastian. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. „Pigment Cell Melanoma Res”. 21 (4), s. 492–493, Aug 2008. DOI: 10.1111/j.1755-148X.2008.00475.x. PMID: 18510589. 
  • X. Jiang, J. Zhou, N.K. Yuen, C.L. Corless i inni. Imatinib targeting of KIT-mutant oncoprotein in melanoma. „Clinical Cancer Research”. 14 (23), s. 7726–7732, Dec 2008. DOI: 10.1158/1078-0432.CCR-08-1144. PMID: 19047099. 
  • X. Wang, L. Si, J. Guo. Treatment algorithm of metastatic mucosal melanoma.. „Chinese Clinical Oncology”. 3 (3), s. 38, Sep 2014. DOI: 10.3978/j.issn.2304-3865.2014.08.04. PMID: 25841464. 
  • S.N. Markovic, V.J. Suman, J.N. Ingle, J.S. Kaur i inni. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. „American Journal of Clinical Oncology”. 29 (4), s. 352–360, Aug 2006. DOI: 10.1097/01.coc.0000217877.78473.a4. PMID: 16891861. 
  • L. Si, X. Xu, Y. Kong, K.T. Flaherty i inni. Major response to everolimus in melanoma with acquired imatinib resistance. „J Clin Oncol”. 30 (4), s. e37-40, Feb 2012. DOI: 10.1200/JCO.2011.37.9644. PMID: 22162580. 
  • B.R. Madewell. Neoplasms in domestic animals: a review of experimental and spontaneous carcinogenesis. „Yale J Biol Med”. 54 (2). s. 111–125. PMID: 7269640. 
  • C.R. Dorn, W.A. Priester. Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. „J Am Vet Med Assoc”. 169 (11), s. 1202–1206, Dec 1976. PMID: 1002589. 
  • E. Kufuor-Mensah, G.L. Watson. Malignant melanomas in a penguin (Eudyptes chrysolophus) and a red-tailed hawk (Buteo jamaicensis). „Vet Pathol”. 29 (4), s. 354–356, Jul 1992. PMID: 1514222. 
  • Vito W. Rebecca, Vernon K. Sondak, Keiran S.M. Smalley, A brief history of melanoma: from mummies to mutations, „Melanoma Res”, 22 (2), 2012, s. 114–22, DOI: 10.1097/CMR.0b013e328351fa4d, PMID: 22395415, PMCID: PMC3303163.
  • D.C. Bodenham. A study of 650 observed malignant melanomas in the South-West region. „Ann R Coll Surg Engl”. 43 (4), s. 218–239, Oct 1968. PMID: 5698493. PMCID: PMC2312310. 
  • Arvin S. Yang, Paul B. Chapman, The history and future of chemotherapy for melanoma, „Hematology/Oncology Clinics of North America”, 23 (3), 2009, 583-97, x, DOI: 10.1016/j.hoc.2009.03.006, PMID: 19464604, PMCID: PMC3904102.

onkologia.org.pl

phmd.pl

sagepub.com

journals.sagepub.com

termedia.pl

thecco.net

viamedica.pl

czasopisma.viamedica.pl

web.archive.org

who.int

wiley.com

onlinelibrary.wiley.com

zalecenia.med.pl

onkologia.zalecenia.med.pl

  • Piotr Rutkowski, Piotr J. Wysocki, Czerniaki skóry [online] [dostęp 2015-09-13] [zarchiwizowane z adresu 2016-03-17].